Prediction of the effect on antihyperglycaemic action of sitagliptin by plasma active form glucagon-like peptide-1

Figure 1 Baseline measurements of homeostasis model assessment of insulin resistance, HOMA-β, insulin, high sensitive C reactive protein, glucagon, and PI/insulin resistance index ratio. Patients’ insulin resistance, insulin and glucagon secretion, and hsCRP at baseline is stratified against plasma active GLP-1 level. Data has been presented by boxplot. ¹Mean statistical significance P < 0.05. GLP-1: Glucagon-like peptide-1; hsCRP: High sensitive C reactive protein.

Figure 2 Hemoglobin A1c and active glucagon-like peptide-1 change by sitagliptin administration. A: Change of HbA1c by sitagliptin administration over six months, the data is presented in mean and S.D. ¹Statistical significance of change of HbA1c between the high active GLP-1 group and the low or middle groups; B: Active GLP-1 level before sitagliptin administration and after three months, stratified by plasma active GLP-1 level. Data is presented as the mean and S.D. ¹Mean statistical significance P < 0.05. GLP-1: Glucagon-like peptide-1; HbA1c: Hemoglobin A1c.

Figure 3 Change in insulin and glucagon secretion, high sensitive C reactive protein during three months of sitagliptin administration stratified against plasma active glucagon-like peptide-1 level at baseline. The data is presented as mean and S.D. *statistical significance of change of HbA1c between the high active GLP-1 group and the low or middle groups. GLP-1: Glucagon-like peptide-1; HbA1c: Hemoglobin A1c.